Richard Salisbury

Richard Salisbury is a CRUK Clinical Research Training Fellow at the University of Oxford, affiliated with Hertford College. His research focuses on molecular mechanisms in haematological malignancies, particularly Chronic Myelomonocytic Leukaemia (CMML).

His core research interests include:

• Haematology
• Oncology
• Epigenetics
• Cancer Research
• Stem Cell Biology
• Molecular Biology

Salisbury investigates TET2 loss-of-function mutations (present in 60% of CMML patients) using multiomic single-cell profiling. His work demonstrates that TET2-mutant haematopoietic stem and progenitor cells (HSPCs) are epigenetically reprogrammed to hijack emergency myelopoiesis pathways, causing hypersensitivity to bone marrow niche cytokines like M-CSF. Current research aims to identify druggable pathways for novel anti-cancer therapies in CMML.

No scientific awards were mentioned in the source material.

No information regarding student advising or research grants was provided in the available text.